{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:13:48Z","timestamp":1793765628410,"version":"4.6.1"},"reference-count":58,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To determine the survival benefit of allogeneic hematopoietic cell transplantation (allo-HCT) in chronic myelomonocytic leukemias (CMML), we assembled a retrospective cohort of CMML patients 18-70 years old diagnosed between 2000 and 2014 from an international CMML dataset (n = 730) and the EBMT registry (n = 384). The prognostic impact of allo-HCT was analyzed through univariable and multivariable time-dependent models and with a multistate model, accounting for age, sex, CMML prognostic scoring system (low or intermediate-1 grouped as lower-risk, intermediate-2 or high as higher-risk) at diagnosis, and AML transformation. In univariable analysis, lower-risk CMMLs had a 5-year overall survival (OS) of 20% with allo-HCT vs 42% without allo-HCT (P &amp;lt; .001). In higher-risk patients, 5-year OS was 27% with allo-HCT vs 15% without allo-HCT (P = .13). With multistate models, performing allo-HCT before AML transformation reduced OS in patients with lower-risk CMML, and a survival benefit was predicted for men with higher-risk CMML. In a multivariable analysis of lower-risk patients, performing allo-HCT before transformation to AML significantly increased the risk of death within 2 years of transplantation (hazard ratio [HR], 3.19; P &amp;lt; .001), with no significant change in long-term survival beyond this time point (HR, 0.98; P = .92). In higher-risk patients, allo-HCT significantly increased the risk of death in the first 2 years after transplant (HR 1.46; P = .01) but not beyond (HR, 0.60; P = .09). Performing allo-HCT before AML transformation decreases life expectancy in lower-risk patients but may be considered in higher-risk patients.<\/jats:p>","DOI":"10.1182\/blood.2021015173","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:52:59Z","timestamp":1654548779000},"page":"1408-1418","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"first","affiliation":[{"name":"1Department of Hematology, Transplantation Division, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-9369","authenticated-orcid":false,"given":"Liesbeth C.","family":"de Wreede","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Bakunina","sequence":"additional","affiliation":[{"name":"4European Bone Marrow Transplantation (EBMT) Statistical Unit, Leiden, Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Immunology, H\u00f4pital Saint-Louis, Assistance Publique H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Koster","sequence":"additional","affiliation":[{"name":"6European Bone Marrow Transplantation (EBMT) Data Office Leiden, Leiden, Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Nazha","sequence":"additional","affiliation":[{"name":"7Cleveland Clinic, Avon Lake, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich W.","family":"Beelen","sequence":"additional","affiliation":[{"name":"8Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[{"name":"9Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Medical Clinic and Policlinic I, University Hospital Dresden, Technical University (TU) Dresden, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[{"name":"11Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk-Jan","family":"Eikema","sequence":"additional","affiliation":[{"name":"4European Bone Marrow Transplantation (EBMT) Statistical Unit, Leiden, Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Radujkovic","sequence":"additional","affiliation":[{"name":"12Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5927","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[{"name":"13Department of Medicine-Hematology, Oncology, Freiburg University Hospital and Medical Faculty, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[{"name":"14King's College Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally B.","family":"Killick","sequence":"additional","affiliation":[{"name":"15The Royal Bournemouth and Christchurch Hospitals National Health Service (NHS) Foundation Trust, Bournemouth, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Legrand","sequence":"additional","affiliation":[{"name":"16Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Canc\u00e9rologie de Marseille, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-1341","authenticated-orcid":false,"given":"Eric","family":"Solary","sequence":"additional","affiliation":[{"name":"17INSERM U1287, Universit\u00e9 Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus","family":"Broom","sequence":"additional","affiliation":[{"name":"18Western General Hospital, Edinburg, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"19Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Rizzoli","sequence":"additional","affiliation":[{"name":"20Department of Hematology, U.O. Ematologia Centro Trapianti Midollo Osseo (CTMO) of Hematology, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hayden","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"22Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"23Bone Marrow Transplantation (BMT) Center - Hematology Unit, Istituto di ricovero e cura a carattere scientifico (IRCCS) Ospedale Maggiore Policlinico Di Milano-University of Milan, Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[{"name":"24INSERM U1286, Centre Hospitalo-Universitaire (CHU) de Lille, Univ. Lille, Infinite, Lille, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[{"name":"4European Bone Marrow Transplantation (EBMT) Statistical Unit, Leiden, Netherlands;"},{"name":"25G\u00e9nomes, biologie cellulaire et th\u00e9rapeutique U944, Universit\u00e9 Paris Cit\u00e9, INSERM, Centre National de la Recherche Scientifique (CNRS), Paris, France"},{"name":"26Service H\u00e9matologie Adultes, H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris, Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2022092215284227600_B1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol."},{"issue":"19","key":"2022092215284227600_B2","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022092215284227600_B3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood."},{"issue":"7","key":"2022092215284227600_B4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia."},{"issue":"7","key":"2022092215284227600_B5","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J."},{"issue":"9","key":"2022092215284227600_B6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbmt.2005.05.008","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"11","author":"Kerbauy","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022092215284227600_B7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2022092215284227600_B8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol."},{"issue":"2","key":"2022092215284227600_B9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13576","article-title":"Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br J Haematol."},{"issue":"1","key":"2022092215284227600_B10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2015.08.031","article-title":"Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for\u00a0patients with chronic myelomonocytic leukemia","volume":"22","author":"Kongtim","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022092215284227600_B11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbmt.2017.11.016","article-title":"Prognostic impact of donor source on allogeneic hematopoietic stem cell transplantation outcomes in adults with chronic myelomonocytic leukemia: a nationwide retrospective analysis in Japan","volume":"24","author":"Itonaga","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2022092215284227600_B12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3324\/haematol.2019.218677","article-title":"Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia","volume":"105","author":"Woo","year":"2020","journal-title":"Haematologica."},{"issue":"2","key":"2022092215284227600_B13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood."},{"issue":"21","key":"2022092215284227600_B14","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol."},{"issue":"30","key":"2022092215284227600_B15","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","volume":"39","author":"Kr\u00f6ger","year":"2021","journal-title":"J Clin Oncol."},{"issue":"30","key":"2022092215284227600_B16","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022092215284227600_B17","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/leu.2015.37","article-title":"HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome a prospective study on behalf of SFGM-TC and GFM","volume":"29","author":"Robin","year":"2015","journal-title":"Leukemia."},{"key":"2022092215284227600_B18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-138680","article-title":"Decitabine versus hydroxyurea for advanced proliferative CMML: results of the Emsco Randomized Phase 3 Dacota Trial","volume":"136","author":"Itzykson","year":"2020","journal-title":"Blood."},{"issue":"2","key":"2022092215284227600_B19","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","article-title":"Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study","volume":"8","author":"Pleyer","year":"2021","journal-title":"Lancet Haematol."},{"issue":"2","key":"2022092215284227600_B20","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1038\/bcj.2015.9","article-title":"Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome","volume":"5","author":"Patnaik","year":"2015","journal-title":"Blood Cancer J."},{"issue":"5","key":"2022092215284227600_B21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood."},{"issue":"15","key":"2022092215284227600_B22","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood."},{"issue":"3","key":"2022092215284227600_B23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica."},{"issue":"1","key":"2022092215284227600_B24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-016-0314-x","article-title":"Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT","volume":"9","author":"Saraceni","year":"2016","journal-title":"J Hematol Oncol."},{"issue":"12","key":"2022092215284227600_B25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2022092215284227600_B26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cmpb.2010.01.001","article-title":"The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models","volume":"99","author":"de Wreede","year":"2010","journal-title":"Comput Methods Programs Biomed."},{"issue":"7","key":"2022092215284227600_B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v038.i07","article-title":"mstate: an R package for the analysis of competing risks and multi-state models","volume":"38","author":"de Wreede","year":"2011","journal-title":"J Stat Softw."},{"key":"2022092215284227600_B28","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.bbmt.2012.10.016","article-title":"Review of multistate models in hematopoietic cell transplantation studies","volume":"19","author":"Logan","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"2022092215284227600_B29","volume-title":"Dynamic Prediction in Clinical Survival Analysis.","author":"van Houwelingen","year":"2012","edition":"1st ed."},{"issue":"1","key":"2022092215284227600_B30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow-up in clinical trials","volume":"9","author":"Shuster","year":"1991","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022092215284227600_B31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.4780030106","article-title":"A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias","volume":"3","author":"Simon","year":"1984","journal-title":"Stat Med."},{"issue":"345","key":"2022092215284227600_B32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/01621459.1974.10480131","article-title":"Evaluation of response-time data involving transient states: an illustration using heart-transplant data","volume":"69","author":"Mantel","year":"1974","journal-title":"J Am Stat Assoc."},{"issue":"1","key":"2022092215284227600_B33","first-page":"95.e1","article-title":"Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"27","author":"Gagelmann","year":"2021"},{"issue":"11","key":"2022092215284227600_B34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41408-020-00387-y","article-title":"Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia","volume":"10","author":"Pophali","year":"2020","journal-title":"Blood Cancer J."},{"issue":"4","key":"2022092215284227600_B35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2015.136846","article-title":"Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion","volume":"101","author":"Eefting","year":"2016","journal-title":"Haematologica."},{"issue":"7","key":"2022092215284227600_B36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23458","article-title":"Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome","volume":"88","author":"Alessandrino","year":"2013","journal-title":"Am J Hematol."},{"issue":"11","key":"2022092215284227600_B37","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/leu.2017.88","article-title":"Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System","volume":"31","author":"Della Porta","year":"2017","journal-title":"Leukemia."},{"issue":"10","key":"2022092215284227600_B38","doi-asserted-by":"crossref","first-page":"e74368","DOI":"10.1371\/journal.pone.0074368","article-title":"Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data","volume":"8","author":"Brand","year":"2013","journal-title":"PLoS One."},{"issue":"11","key":"2022092215284227600_B39","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41375-018-0143-8","article-title":"Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases","volume":"32","author":"Patnaik","year":"2018","journal-title":"Leukemia."},{"issue":"6","key":"2022092215284227600_B40","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2020.02.019","article-title":"Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation?","volume":"26","author":"Ruggiu","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022092215284227600_B41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/bjh.15819","article-title":"Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia","volume":"185","author":"Kr\u00f6ger","year":"2019","journal-title":"Br J Haematol."},{"issue":"1","key":"2022092215284227600_B42","first-page":"52","article-title":"Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system","volume":"6","author":"Aul","year":"1992","journal-title":"Leukemia."},{"issue":"6","key":"2022092215284227600_B43","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"issue":"3","key":"2022092215284227600_B44","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood."},{"issue":"6","key":"2022092215284227600_B45","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer."},{"issue":"12","key":"2022092215284227600_B46","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood."},{"issue":"17","key":"2022092215284227600_B47","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022092215284227600_B48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbmt.2019.10.015","article-title":"Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant: a retrospective study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Carr\u00e9","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022092215284227600_B49","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/bloodadvances.2020003600","article-title":"A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation","volume":"5","author":"Gagelmann","year":"2021","journal-title":"Blood Adv."},{"issue":"2","key":"2022092215284227600_B50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","article-title":"Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis","volume":"12","author":"Togami","year":"2022","journal-title":"Cancer Discov."},{"issue":"6","key":"2022092215284227600_B51","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/10428194.2016.1246726","article-title":"Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)","volume":"58","author":"DeZern","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"2022092215284227600_B52","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/bmt.2016.295","article-title":"Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome","volume":"52","author":"Yahng","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"23","key":"2022092215284227600_B53","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022092215284227600_B54","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.bbmt.2012.05.003","article-title":"Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine","volume":"18","author":"Platzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"19","key":"2022092215284227600_B55","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med."},{"issue":"25","key":"2022092215284227600_B56","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med."},{"issue":"8","key":"2022092215284227600_B57","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood."},{"issue":"6","key":"2022092215284227600_B58","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"HemaSphere."}],"updated-by":[{"DOI":"10.1182\/blood.2023020947","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/12\/1408\/1921377\/bloodbld2021015173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/12\/1408\/1921377\/bloodbld2021015173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T15:39:43Z","timestamp":1663861183000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/12\/1408\/485477\/Role-of-allogeneic-transplantation-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021015173","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/blood.2023020947","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}